Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

19.6 (USD) • At close September 6, 2024
Bedrijfsnaam Catalyst Pharmaceuticals, Inc.
Symbool CPRX
Munteenheid USD
Prijs 19.6
Beurswaarde 2,326,284,800
Dividendpercentage 0%
52-weken bereik 11.55 - 20.87
Industrie Biotechnology
Sector Healthcare
CEO Mr. Patrick J. McEnany
Website https://www.catalystpharma.com

An error occurred while fetching data.

Over Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of

Vergelijkbare Aandelen

IGM Biosciences, Inc. logo

IGM Biosciences, Inc.

IGMS

9.31 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.59 USD

TG Therapeutics, Inc. logo

TG Therapeutics, Inc.

TGTX

22.03 USD

DocGo Inc. logo

DocGo Inc.

DCGO

3.63 USD

Theravance Biopharma, Inc. logo

Theravance Biopharma, Inc.

TBPH

8.01 USD

Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT

3.59 USD

Pulmonx Corporation logo

Pulmonx Corporation

LUNG

7.31 USD

Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp.

AVXL

5.15 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)